BLAU3
ONconsolidatedBlau Farmacêutica S.A.
CNPJ 58430828000160
—
Price step on 2026-01-06, consistent with a reverse split or split. High, low and change count from that day on — B3's file does not adjust the past, and mixing both steps would compare different share bases. The chart shows the raw series.
Ratios
Q3 25 → Q2 26Share capital from the FRE dated 2026-12-31. The FRE is annual — buybacks and issuances after that date are not reflected here.
computed — The CVM does not publish Q4 on its own — the annual filing carries the full year. This figure is the year minus the first nine months.
Distributions
| Type | Approved on | Ex-date basis | R$ / share |
|---|---|---|---|
| JRS CAP PROPRIO | 2026-09-24 | 2026-09-29 | 0.075763 |
| JRS CAP PROPRIO | 2026-06-22 | 2026-06-25 | 0.075763 |
| JRS CAP PROPRIO | 2026-03-18 | 2026-03-23 | 0.075763 |
| DIVIDENDO | 2025-12-15 | 2025-12-18 | 0.562807 |
| JRS CAP PROPRIO | 2025-12-01 | 2025-12-04 | 0.112561 |
| JRS CAP PROPRIO | 2025-09-18 | 2025-09-23 | 0.095677 |
| JRS CAP PROPRIO | 2025-03-18 | 2025-03-21 | 0.105526 |
| JRS CAP PROPRIO | 2025-03-18 | 2025-03-21 | 0.147737 |
| JRS CAP PROPRIO | 2024-09-23 | 2024-09-26 | 0.084421 |
| JRS CAP PROPRIO | 2024-06-21 | 2024-06-26 | 0.140702 |
| DIVIDENDO | 2024-04-29 | 2024-04-29 | 0.013983 |
| JRS CAP PROPRIO | 2024-03-19 | 2024-03-22 | 0.125218 |
Gross amounts, by record date, from B3's registry — the Type column separates dividends, interest on equity and capital returns, and the 12-month yield adds all of them. A capital return is a refund, not income. Interest on equity (JCP) carries 15% withholding tax for individuals — the net yield is lower. Payment dates are not in this registry; they live in the shareholder notice.
Ratios by year
| Year | Revenue | Net income | Gross margin | Net margin | ROE | ROA | Turnover | Year-end price | P/E | DY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.70bn | 296.77m | 40.1% | 17.4% | 13.2% | 8.2% | 0.47 | 14.05 | — | 7.3% |
| 2024 | 1.75bn | 213.53m | 37.6% | 12.2% | 9.9% | 6.3% | 0.51 | 13.15 | 10.78 | 2.8% |
| 2023 | 1.37bn | 247.49m | 35.7% | 18.0% | 12.4% | 8.1% | 0.45 | 16.41 | 11.64 | 2.6% |
| 2022 | 1.41bn | 360.49m | 47.5% | 25.6% | 19.8% | 14.4% | 0.56 | 26.32 | 12.90 | 3.2% |
| 2021 | 1.37bn | 323.86m | 48.7% | 23.7% | 19.8% | 13.9% | 0.59 | 36.40 | 19.26 | 0.7% |
| 2020 | 1.18bn | 254.33m | 47.0% | 21.5% | 114.9% | 20.0% | 0.93 | — | — | — |
| 2019 | 977.50m | 200.24m | 44.0% | 20.5% | 75.4% | 27.1% | 1.32 | — | — | — |
| 2018 | 782.17m | 123.25m | 43.3% | 15.8% | 55.2% | 20.7% | 1.32 | — | — | — |
| 2017 | 617.66m | 103.13m | 45.4% | 16.7% | 74.6% | 28.2% | 1.69 | — | — | — |
From each fiscal year's DFP, with the close of the fiscal year-end month alongside. Yearly P/E and DY use the fiscal year-end close against that year's EPS and payouts — both already per share. An empty cell carries its reason in the tooltip: a loss, EPS out of scale, lot-of-a-thousand quoting, a split in the way. Yearly P/B is left out: it would need that year's share count, and the registration filing stores the latest approval's count under the reference date.
Quarterly results
| Period | Revenue | Operating | Net income | Net margin |
|---|---|---|---|---|
| Q2 26 | 486.60m | 83.35m | 55.54m | 11.4% |
| Q1 26 | 434.97m | 85.24m | 36.29m | 8.3% |
| Q4 25 | 389.36m | 48.54m | 37.38m | 9.6% |
| Q3 25 | 475.20m | 91.59m | 105.52m | 22.2% |
| Q2 25 | 464.83m | 103.75m | 63.18m | 13.6% |
| Q1 25 | 373.00m | 110.52m | 90.69m | 24.3% |
| Q4 24 | 456.03m | 102.43m | 57.02m | 12.5% |
| Q3 24 | 473.57m | 105.46m | 69.21m | 14.6% |
| Q2 24 | 465.10m | 72.08m | 47.62m | 10.2% |
| Q1 24 | 359.68m | 48.84m | 39.67m | 11.0% |
| Q4 23 | 387.48m | 39.55m | 26.94m | 7.0% |
| Q3 23 | 362.65m | 152.37m | 98.92m | 27.3% |
Balance sheet
| Period | Total assets | Equity | Assets / Equity | Current ratio |
|---|---|---|---|---|
| Q2 26 | 4.03bn | 2.32bn | 1.74 | 3.23 |
| Q1 26 | 3.57bn | 2.28bn | 1.57 | 2.66 |
| Q4 25 | 3.64bn | 2.26bn | 1.61 | 2.47 |
| Q3 25 | 3.62bn | 2.33bn | 1.55 | 2.90 |
| Q2 25 | 3.47bn | 2.25bn | 1.54 | 3.17 |
| Q1 25 | 3.43bn | 2.19bn | 1.57 | 3.23 |
| Q4 24 | 3.41bn | 2.15bn | 1.59 | 3.12 |
| Q3 24 | 3.24bn | 2.08bn | 1.55 | 3.48 |
| Q2 24 | 3.10bn | 2.03bn | 1.52 | 3.98 |
| Q1 24 | 3.16bn | 2.01bn | 1.57 | 3.82 |
| Q4 23 | 3.05bn | 2.00bn | 1.53 | 4.63 |
| Q3 23 | 3.07bn | 1.97bn | 1.56 | 3.44 |
A balance sheet is a snapshot, not a window: there is no “computed Q4” here — December's figure is what the annual filing published.
What the company filed
| Filing | Period | Filed on | Days after close | Document |
|---|---|---|---|---|
| ITRT2 | 2026-06-30 | 2026-08-11 | 42 | CVM ↗ |
| ITRT1 | 2026-03-31 | 2026-05-07 | 37 | CVM ↗ |
| DFPanual | 2025-12-31 | 2026-03-17 | 76 | CVM ↗ |
| ITRT3 | 2025-09-30 | 2025-11-04 | 35 | CVM ↗ |
| ITRT2 | 2025-06-30 | 2025-08-05 | 36 | CVM ↗ |
| ITRT1 | 2025-03-31 | 2025-05-06 | 36 | CVM ↗ |
| DFPanual | 2024-12-31 | 2025-03-18 | 77 | CVM ↗ |
| ITRT3 | 2024-09-30 | 2024-11-05 | 36 | CVM ↗ |
| ITRT2 | 2024-06-30 | 2024-08-06 | 37 | CVM ↗ |
| ITRT1 | 2024-03-31 | 2024-05-07 | 37 | CVM ↗ |
| DFPanual | 2023-12-31 | 2024-03-19 | 79 | CVM ↗ |
| ITRT3 | 2023-09-30 | 2023-11-08 | 39 | CVM ↗ |
| ITRT2 | 2023-06-30 | 2023-08-09 | 40 | CVM ↗ |
| ITRT1 | 2023-03-31 | 2023-05-04 | 34 | CVM ↗ |
| DFPanual | 2022-12-31 | 2023-03-01 | 60 | CVM ↗ |
| ITRT3 | 2022-09-30 | 2022-11-03 | 34 | CVM ↗ |
When the next one is due
This is measured habit, not company guidance: the CVM publishes no forward calendar as open data. The estimate applies this company's historical median to the next period.